Evidence of androgen action in endometrial and ovarian cancers
The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Abstract
Endometrial cancer (EC) and ovarian cancer are common gynaecological malignancies. The impact of androgen action in these cancers is poorly understood; however, there is emerging evidence to suggest that targeting androgen signalling may be of therapeutic benefit. Epidemiological evidence suggests that there is an increased risk of EC associated with exposure to elevated levels of androgens, and genetic variants in genes related to both androgen biosynthesis and action are associated with an increased risk of both EC and ovarian cancer. Androgen receptors (ARs) may be a potential therapeutic target in EC due to reported anti-proliferative activities of androgens. By contrast, androgens may promote growth of some ovarian cancers and anti-androgen therapy has been proposed. Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. This review considers the evidence that androgens may be important in the aetiology of EC and ovarian cancer with discussion of evidence for androgen action in normal and malignant endometrial and ovarian tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison between the patterns of expression of receptor proteins in normal endometrium with samples of endometrial cancer and endometriosis lesions has revealed evidence of aberrant expression of both AR and ERs, which may result in novel disease-specific targets for the action of steroids generated by intracrine activation/metabolism discussed below.”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293 · cited 2×
“In the UK, it is the fifth most common female cancer (http://www.cancerresearchuk.org/) consistent with higher incidence in high-resource countries (Ferlay et al. 2010).”
BackgroundIntegrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784 · cited 1×
“One of the most studied polymorphisms of the AR NTD is the CAG-repeat sequence encoding poly-glutamine repeats (Spada et al. 1991).”
BackgroundTHE JOURNAL OF REPRODUCTIVE MEDICINE: PATIENT ANXIETY DURING GYNECOLOGIC EXAMINATIONS
Reddy, D. M., & Wasserman, S. A. (1999) · American Journal of Nursing · doi:10.1097/00000446-199901000-00024 · Cited by 2,483
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364 · cited 1×
“According to a recent report from FIGO, ovarian cancer is the seventh most common cancer in women worldwide (Prat 2013).”
BackgroundChamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,156 · cited 1×
“The length of the CAG-repeat region correlates inversely with AR transactivation capability (Chamberlain et al. 1994).”
BackgroundMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Cloning of Human Androgen Receptor Complementary DNA and Localization to the X Chromosome
Lubahn, D. B., Joseph, D. R., Sullivan, P. M., Willard, H. F., French, F. S., & Wilson, E. M. (1988) · Science · doi:10.1126/science.3353727 · Cited by 1,016 · cited 1×
“The gene encoding human AR is located on the X chromosome (Lubahn et al. 1988).”
BackgroundPearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939 · cited 3×
“Pooled analysis of 13 case–control studies found that endometriosis was associated with an increased risk of clear cell, low-grade serous and endometrioid invasive but not mucinous tumours (Pearce et al. 2012).”
BackgroundInfluentialOvarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937 · cited 1×
“In current users, risks varied considerably according to cancer histology (Beral et al. 2007).”
BackgroundAltered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829 · cited 2×
“Mutations in PTEN are common in EC and this leads to inactivation and loss of PTEN expression, which is an early diagnostic marker for endometrial pre-cancers (Mutter et al. 2000a).”
BackgroundType I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan, V. W., Yang, H. P., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y.-B., Wolk, A., Wentzensen, N., Weiss, N. S., Webb, P. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.2596 · Cited by 827 · cited 2×
“…oestrogenindependent, new evidence suggests that both types I and II ECs share many common risk factors, including age at menarche, parity and contraceptive use which may indicate that changes in steroid exposure has an impact on the risk of developing either type I or II EC (Setiawan et al. 2013).”
BackgroundFranks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Piek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787 · cited 1×
“For example, cells within the fallopian tube epithelium have been proposed as the cell type(s) contributing to low- and high-grade serous carcinomas (Piek et al. 2001).”
BackgroundOverweight as an avoidable cause of cancer in Europe
Bergström, A., Pisani, P., Tenet, V., Wolk, A., & Adami, H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1053>3.0.co;2-t · Cited by 758 · cited 2×
“Furthermore, an analysis of EC cases in European women estimated that obesity accounted for 39% of cases (Bergstrom et al. 2001), an association usually attributed to excess exposure to oestrogens as adipose tissue is the primary site of oestrogen production in post-menopausal women (Simpson et al.”
BackgroundGranulosa Cell Tumor of the Ovary
Schumer, S. T., & Cannistra, S. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.019 · Cited by 674
Endometrial cancer and hormone-replacement therapy in the Million Women Study
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66455-0 · Cited by 613 · cited 2×
“1530/ERC-13-0551 Printed in Great Britain following the inclusion of progestins in HRT formulations that significantly decrease risk of EC due to the antiproliferative effects of progestins on the endometrium (Beral et al. 2005).”
InfluentialRisk and prognosis of endometrial cancer after tamoxifen for breast cancer
Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02677-5 · Cited by 541
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K. H., Fishman, D., et al. (2004) · Nature Medicine · doi:10.1038/nm1125 · Cited by 509 · cited 2×
“…woman with an ovarian adenocarcinoma) reported that 121 genes were up-regulated (Sheach et al. 2009) including Ras-related protein, RAB25 (RAB25), a small GTPase implicated in vesicle trafficking and cancer metastasis previously shown to be over-expressed in aggressive cancers (Cheng et al. 2004).”
BackgroundCovalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1)
Poukka, H., Karvonen, U., Jänne, O. A., & Palvimo, J. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14145 · Cited by 457 · cited 1×
“AR sumoylation has been demonstrated to enrich AR in the nuclear matrix under conditions of cellular stress, causing attenuation of the transcriptional activity of AR, contributing to defective androgen signalling in cancer (Poukka et al. 2000, Rytinki et al. 2012).”
BackgroundSieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433 · cited 3×
“Additional studies have reported that the protective effect of tubal ligation is subtype specific with risk reduction for invasive endometrioid and clear cell cancers (Sieh et al. 2013b).”
BackgroundMethodEpidemiology of Endometrial Cancer 2
Elwood, J. M., Cole, P., Rothman, K. J., & Kaplan, S. D. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/59.4.1055 · Cited by 430
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 398
(1997) · PubMed · Cited by 363
Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome
Hart, R., Hickey, M., & Franks, S. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.05.001 · Cited by 358 · cited 1×
“Polycystic ovarian syndrome (PCOS) is an endocrine disorder affecting women of reproductive age and is associated with menstrual cycle disturbances, hyperandrogenism and infertility (Hart et al. 2004).”
BackgroundPolymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women
Dunning, A. M., Dowsett, M., Healey, C. S., Tee, L., Luben, R. N., Folkerd, E., Novik, K. L., Kelemen, L., Ogata, S., Pharoah, P. D. P., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh167 · Cited by 346 · cited 1×
“An association between single nucleotide polymorphisms (SNPs) in CYP19A1 with oestrogen concentrations (both oestrones (E1) and E2) and oestrogen:testosterone ratios has been described in post-menopausal women (Dunning et al. 2004).”
BackgroundNew insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 317 · cited 1×
“Approximately 90% of ovarian tumours are carcinomas (malignant epithelial tumours) with five main types being distinguished based on histopathology and molecular genetic analysis (Prat 2012, Tan et al. 2013).”
BackgroundSubfertility and defective folliculogenesis in female mice lacking androgen receptor
Hu, Y.-C., Wang, P.-H., Yeh, S., Wang, R.-S., Xie, C., Xu, Q., Zhou, X., Chao, H.-T., Tsai, M.-Y., & Chang, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404372101 · Cited by 315 · cited 3×
“Studies on AR knockout (ARKO) female mice have shown that they have normal reproductive tracts under macroscopic examination but are subfertile (Hu et al. 2004).”
BackgroundInfluentialRecent Progress in Hormone Research
Magid, G. J. (1967) · American Journal of Clinical Pathology · doi:10.1093/ajcp/48.1.48 · Cited by 310
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281 · cited 1×
“Approximately 90% of ovarian tumours are carcinomas (malignant epithelial tumours) with five main types being distinguished based on histopathology and molecular genetic analysis (Prat 2012, Tan et al. 2013).”
BackgroundSyed, V., Ulinski, G., Mok, S. C., Yiu, G. K., & Ho, S. (2001) · PubMed · Cited by 275
Allen, N. E., Key, T. J., Dossus, L., Rinaldi, S., Cust, A., Lukanova, A., Peeters, P. H., Onland-Moret, N. C., Lahmann, P. H., Berrino, F., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0064 · Cited by 268 · cited 3×
“The Million Women Study identified that BMI was a major modifiable risk factor and that as many as half of the EC cases in post-menopausal women could be attributed to being obese or overweight (Reeves et al. 2007).”
BackgroundResultElevated Endometrial Androgen Receptor Expression in Women with Polycystic Ovarian Syndrome1
Apparao, K. B. C., Lovely, L. P., Gui, Y., Lininger, R. A., & Lessey, B. A. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.2.297 · Cited by 265 · cited 2×
“It has been reported that ARs are expressed in the endometrium throughout the menstrual cycle (Mertens et al. 2001, Apparao et al. 2002, Marshall et al. 2011).”
BackgroundKorch, C., Spillman, M. A., Jackson, T. A., Jacobsen, B. M., Murphy, S. K., Lessey, B. A., Jordan, V. C., & Bradford, A. P. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.017 · Cited by 251 · cited 2×
“Results reported for some endometrial cell lines may be unreliable due to cross-contamination with other cancer cells (Korch et al. 2012).”
BackgroundDiverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231 · cited 1×
“Intra- and inter-molecular interactions between domains are important for the receptor’s activation capacity (reviewed in Claessens et al. (2008)).”
BackgroundZhu, M., & Kyprianou, N. (2010) · The FASEB Journal · doi:10.1096/fj.09-136994 · Cited by 226 · cited 1×
“Recent studies on prostate cancer epithelial cells indicate that androgens induce EMT, migration and invasion of prostatic epithelial cells (Zhu & Kyprianou 2010).”
BackgroundExpanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)
Gao, W., & Dalton, J. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.003 · Cited by 215 · cited 1×
“Furthermore, the generation of selective AR modulators (SARMs) has revolutionised the potential manipulation of androgenic stimulation in a therapeutic context (Gao & Dalton 2007).”
BackgroundEpidemiology of endometrial cancer
Purdie, D. M., & Green, A. C. (2001) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2000.0180 · Cited by 207 · cited 2×
“Established risk factors for developing EC are associated with increased exposure to oestrogens throughout the reproductive lifespan such as nulliparity, early menarche and late menopause (Purdie & Green 2001).”
BackgroundPaik, D. Y., Janzen, D. M., Schafenacker, A. M., Velasco, V. S., Shung, M. S., Cheng, D., Huang, J., Witte, O. N., & Memarzadeh, S. (2012) · STEM CELLS · doi:10.1002/stem.1207 · Cited by 193 · cited 1×
“Stem-like epithelial cells from the distal end of the fallopian tube capable of clonal growth and self-renewal have also been identified which may play a role in the initiation of serous tumours, although the impact of androgens on this cell population has not been investigated (Paik et al. 2012).”
BackgroundHormonal interactions in endometrial cancer.
Emons, G., Fleckenstein, G., Hinney, B., Huschmand, A., & Heyl, W. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070227 · Cited by 192 · cited 2×
“Consistent with the anti-proliferative effect of progestins, use of the combined oral contraceptive pill is considered as protective against EC risk (Emons et al. 2000).”
BackgroundMontgomery, B. T., Young, C. Y. ‐., Bilhartz, D. L., Andrews, P. E., Thompson, N. F., Tindall, D. J., & Prescott, J. L. (1992) · The Prostate · doi:10.1002/pros.2990210107 · Cited by 178 · cited 1×
“Prostate-specific antigen (PSA/KLK3) is an androgenregulated gene that has been extensively investigated in the context of prostate cancer (Montgomery et al. 1992).”
BackgroundSaunders, P. T. K., Millar, M. R., Williams, K., Macpherson, S., Harkiss, D., Anderson, R. A., Orr, B., Groome, N. P., Scobie, G., & Fraser, H. M. (2000) · Biology of Reproduction · doi:10.1095/biolreprod63.4.1098 · Cited by 175 · cited 4×
“ARs are expressed in somatic cells within the human ovary in both foetal and adult life (Saunders et al. 2000, Fowler et al. 2011).”
BackgroundInfluentialSelf-citationTubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
Sieh, W., Salvador, S., McGuire, V., Weber, R. P., Terry, K. L., Rossing, M. A., Risch, H., Wu, A. H., Webb, P. M., Moysich, K., et al. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt042 · Cited by 170
The Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 169 · cited 2×
“…the surface epithelium, as malignant transformation of this cell type has been implicated in development of epithelial ovarian cancers following formation of inclusion cysts (Rabban & Bell 2005) although which subtypes this is associated with is currently being re-evaluated (Berns & Bowtell 2012).”
BackgroundSTRUCTURAL ORGANIZATION OF THE HUMAN ANDROGEN RECEPTOR GENE
Kuiper, G. G. J. M., Faber, P. W., van Rooij, H. C. J., van der Korput, J. A. G. M., Ris-Stalpers, C., Klaassen, P., Trapman, J., & Brinkmann, A. O. (1989) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.002r001 · Cited by 168 · cited 1×
“Cloning has identified eight exons with conserved domains in common with other steroid hormone receptors (Kuiper et al. 1989).”
BackgroundThe Australian Ovarian Cancer Study Group and The Australian National Endometrial Cancer Study Group, Fearnley, E. J., Marquart, L., Spurdle, A. B., Weinstein, P., & Webb, P. M. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9658-7 · Cited by 162 · cited 10×
“PCOS and EC share many of the same risk factors and a recent population-based case–control study in Australia found that women with PCOS have a fourfold increased risk of EC compared with women without PCOS (Fearnley et al. 2010).”
BackgroundResultInfluentialAKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer
Rižner, T. L., Šmuc, T., Rupreht, R., Šinkovec, J., & Penning, T. M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.009 · Cited by 159 · cited 1×
“Rizner et al. (2006) showed that dysregulation of AKR1C3 (also known as 17bHSD5), which converts A4 to testosterone, is associated with EC with increased mRNA expression in malignant endometrium compared with normal endometrium.”
BackgroundGenomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
Tan, D. S. P., Iravani, M., McCluggage, W. G., Lambros, M. B. K., Milanezi, F., Mackay, A. G., Gourley, C., Geyer, F. C., Vatcheva, R., Millar, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1688 · Cited by 158 · cited 1×
“Although historically often treated as a single disease entity, new evidence has revealed that histologically similar ovarian cancers may differ in their tissues of origin, their genetic abnormalities and their responsiveness to chemotherapy (Tan et al. 2011).”
BackgroundHeight, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort Studies
Schouten, L. J., Rivera, C., Hunter, D. J., Spiegelman, D., Adami, H.-O., Arslan, A., Beeson, W. L., van den Brandt, P. A., Buring, J. E., Folsom, A. R., et al. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2524 · Cited by 151 · cited 1×
“7 m and ovarian cancer risk especially in pre-menopausal women (Schouten et al. 2008).”
BackgroundCancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis
Borgfeldt, C., & Andolf, E. (2004) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/j.0001-6349.2004.00305.x · Cited by 149
Location and developmental regulation of androgen receptor in primate ovary
Hillier, S. G., Tetsuka, M., & Fraser, H. M. (1997) · Human Reproduction · doi:10.1093/humrep/12.1.107 · Cited by 148 · cited 1×
“In primate ovaries, expression of AR was most abundant in immature follicles (Hillier et al. 1997).”
BackgroundDossus, L., Lukanova, A., Rinaldi, S., Allen, N., Cust, A. E., Becker, S., Tjonneland, A., Hansen, L., Overvad, K., Chabbert-Buffet, N., et al. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws309 · Cited by 148 · cited 2×
“Using data collected in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, factor analysis of 233 cases of EC with 446 matched controls identified three factors associated with increased post-menopausal EC risk: ‘insulin resistance’, ‘steroids’ and ‘inflammation’ (Dossus et al. 2013).”
BackgroundMethodWalters, K. A., Allan, C. M., Jimenez, M., Lim, P. R., Davey, R. A., Zajac, J. D., Illingworth, P., & Handelsman, D. J. (2007) · Endocrinology · doi:10.1210/en.2007-0248 · Cited by 146
Zhao, H., Dupont, J., Yakar, S., Karas, M., & LeRoith, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207162 · Cited by 142 · cited 1×
“The tumour suppressor gene phosphatase and tensin homologue deleted on chromosome 10 (encoded by PTEN) regulates cell growth, apoptosis and proliferation (Zhao et al. 2004).”
BackgroundMertens, H. J. M. M., Heineman, M. J., Theunissen, P. H. M. H., de Jong, F. H., & Evers, J. L. H. (2001) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(00)00554-6 · Cited by 142 · cited 1×
“It has been reported that ARs are expressed in the endometrium throughout the menstrual cycle (Mertens et al. 2001, Apparao et al. 2002, Marshall et al. 2011).”
BackgroundHorie, K., Takakura, K., Fujiwara, H., Suginami, H., Liao, S., & Mori, T. (1992) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a137614 · Cited by 142 · cited 3×
“Although some authors have claimed that AR is detected in glandular epithelium throughout the menstrual cycle (Horie et al. 1992), we and others have reported that immunoexpression is up-regulated in the glandular epithelium in the mid/late secretory phase at a time when progesterone concentrations…”
BackgroundInfluentialHormone response in ovarian cancer: time to reconsider as a clinical target?
Modugno, F., Laskey, R. A., Smith, A. L., Andersen, C. L., Haluska, P., & Oesterreich, S. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0175 · Cited by 142 · cited 6×
“Ovarian cancer risk is consistently reported as being reduced by factors that interrupt ovulation, including use of oral contraceptives, pregnancy or breastfeeding (Modugno et al. 2012) as well as tubal ligation with the latter most closely associated with endometrioid tumours (Rice et al. 2013).”
BackgroundResultInfluentialElevated Production and Metabolic Clearance Rates of Androgens in Morbidly Obese Women
SAMOJLIK, E., KIRSCHNER, M. A., SILBER, D., SCHNEIDER, G., & ERTEL, N. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-5-949 · Cited by 139 · cited 1×
“Interestingly, a study from the 1980s by Samojlik et al. (1984) examined androgen production in morbidly obese, non-hirsute, normally menstruating women and found that testosterone and dihydrotestosterone (DHT) production rates were elevated twofold compared with controls, but that this increased…”
BackgroundCyclin D1 gene (CCND1) mutations in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Hardisson, D., Sarrió, D., Prat, J., Cigudosa, J. C., Matías‐Guiu, X., & Palacios, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206868 · Cited by 136 · cited 2×
“CCND1 expression is significantly associated with EC grade (Moreno-Bueno et al. 2003) with a recent study suggested that cyclin D1 may be a prognostic marker for endometrial diseases with overexpression of cyclin D1 in EC and atypical complex hyperplasia (Liang et al.”
BackgroundRegulation of the androgen receptor by post-translational modifications
Coffey, K., & Robson, C. N. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0238 · Cited by 135 · cited 1×
“…q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0551 Printed in Great Britain AR is the target of several post-translational modifications including acetylation, phosphorylation, methylation, ubiquitination and sumoylation (reviewed in Coffey & Robson (2012)).”
BackgroundInfluentialAllosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
Kumar, R., & McEwan, I. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1033 · Cited by 135 · cited 1×
“Phosphorylation of serine residues in the NTD of AR can result from ligand activation as well as growth factor and other signalling cascades, which in turn can influence the secondary structure of the domain (reviewed in Kumar & McEwan (2012)).”
BackgroundRevised FIGO Staging System for Endometrial Cancer
Lewin, S. N. (2011) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182185baa · Cited by 131 · cited 2×
“Clinically, ECs are graded according to the FIGO system (revised in 2009 (Lewin 2011)) and have classically been divided into two subtypes: oestrogen-dependent type I and the less common, but clinically more aggressive, oestrogenindependent type II (Emons et al.”
Changes in Endometrial PTEN Expression throughout the Human Menstrual Cycle1
Mutter, G. L., Lin, M.-C., Fitzgerald, J. T., Kum, J. B., & Eng, C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6652 · Cited by 128 · cited 2×
“Mutations in PTEN are common in EC and this leads to inactivation and loss of PTEN expression, which is an early diagnostic marker for endometrial pre-cancers (Mutter et al. 2000a).”
BackgroundWalters, K. A., Middleton, L. J., Joseph, S. R., Hazra, R., Jimenez, M., Simanainen, U., Allan, C. M., & Handelsman, D. J. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.112.102012 · Cited by 125 · cited 1×
“Female mice with targeted deletion of Ar in granulosa are also subfertile confirming the importance of AR expression in granulosa cells for normal ovarian function (Walters et al. 2012).”
BackgroundAuersperg, N. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.021 · Cited by 120 · cited 2×
“Although there is still evidence to support OSE cells as the originating cell type for some ovarian cancers (Auersperg 2013), the fact that both OSE cells and cells within the fallopian tube epithelium express AR (Edmondson et al.”
BackgroundAndrogen receptor function is modulated by the tissue‐specific AR45 variant
Ahrens‐Fath, I., Politz, O., Geserick, C., & Haendler, B. (2005) · The FEBS Journal · doi:10.1111/j.1432-1033.2004.04395.x · Cited by 119 · cited 8×
“In addition, a novel 45 kDa AR isoform (AR45) that was discovered in 2005 was found to be expressed in the uterus and shown to be a negative regulator of AR by interacting with the AR NTD (Ahrens-Fath et al. 2004). http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0551 Printed…”
BackgroundInfluentialOlson, S. H., Bandera, E. V., & Orlow, I. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk015 · Cited by 117 · cited 3×
“Olson et al. (2007) reviewed the association between variants in steroid biosynthetic genes, circulating hormones and EC risk by summarising available data for seven genes in the oestrogen biosynthesis pathway.”
BackgroundInfluentialJordan, S. J., Green, A. C., Whiteman, D. C., Moore, S. P., Bain, C. J., Gertig, D. M., Webb, P. M., & for the Australian Cancer Study Group (ovarian cancer) and the Australian Ovarian Cancer Study Group (2008) · International Journal of Cancer · doi:10.1002/ijc.23287 · Cited by 115
Fowler, P. A., Anderson, R. A., Saunders, P. T., Kinnell, H., Mason, J. I., Evans, D. B., Bhattacharya, S., Flannigan, S., Franks, S., Monteiro, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2618 · Cited by 115 · cited 1×
“ARs are expressed in somatic cells within the human ovary in both foetal and adult life (Saunders et al. 2000, Fowler et al. 2011).”
BackgroundSelf-citationVisualising androgen receptor activity in male and female mice
Dart, D. A., Waxman, J., Aboagye, E. O., & Bevan, C. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071694 · Cited by 112 · cited 2×
“R e la te d C a n ce r demonstrating the direct action of androgens in these tissues (Dart et al. 2013).”
BackgroundDifferential regulation of PTEN expression by androgen receptor in prostate and breast cancers
Wang, Y., Romigh, T., He, X., Tan, M.-H., Orloff, M., Silverman, R. H., Heston, W. D. W., & Eng, C. (2011) · Oncogene · doi:10.1038/onc.2011.144 · Cited by 101 · cited 1×
“The impact of androgens on PTEN expression in the endometrium is unknown and likely to be cell context dependent as AR-dependent signalling inhibits PTEN expression in prostate cancer cells whereas stimulation of AR signalling up-regulates PTEN expression in breast cancer cells (Wang et al. 2011).”
BackgroundChanges in Endometrial PTEN Expression throughout the Human Menstrual Cycle
Mutter, G. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2334 · Cited by 100
Epithelial ovarian cancer: testing the 'androgens hypothesis'
Olsen, C. M., Green, A. C., Nagle, C. M., Jordan, S. J., Whiteman, D. C., Bain, C. J., Webb, P. M., & on behalf of the Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0075 · Cited by 100 · cited 1×
“…invasive epithelial ovarian cancer or borderline malignant tumour, there was no evidence that excess androgens due to PCOS or treatment with the synthetic androgen Danazol were correlated with overall risk of ovarian cancer but PCOS did increase the risk of borderline tumours (Olsen et al. 2008).”
BackgroundWalters, K. A., McTavish, K. J., Seneviratne, M. G., Jimenez, M., McMahon, A. C., Allan, C. M., Salamonsen, L. A., & Handelsman, D. J. (2009) · Endocrinology · doi:10.1210/en.2008-1750 · Cited by 99 · cited 1×
“A study utilising reciprocal paired ovarian transplantation between ArC/C and ArK/K mice revealed that host ArK/K female mice with ArC/C ovarian transplants had defective uterine growth consistent with an intrauterine role for androgens in this species (Walters et al. 2009).”
BackgroundThe orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion
Chand, A. L., Herridge, K. A., Thompson, E. W., & Clyne, C. D. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0179 · Cited by 99 · cited 2×
“As LRH1 is an orphan receptor that has been implicated in promoting invasion and migration of breast cancer cells independent of oestrogen action (Chand et al. 2010), any increase in expression as a result of androgen action might promote invasiveness of granulosa cells and it is notable that LRH1…”
BackgroundNeed, E. F., Selth, L. A., Harris, T. J., Birrell, S. N., Tilley, W. D., & Buchanan, G. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1314 · Cited by 97 · cited 2×
“For example, studies on the breast have considered two aspects: anti-androgenic effects of the progestin MPA (Ochnik et al. 2014) and crosstalk between AR and ERa signalling due to overlapping binding sites withinDNA(Need et al. 2012,Ochnik et al. 2014).”
BackgroundMethodGuzeloglu-Kayisli, O., Kayisli, U. A., Al-Rejjal, R., Zheng, W., Luleci, G., & Arici, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030414 · Cited by 95 · cited 1×
“Guzeloglu-Kayisli et al. (2003) reported that E2 promoted PTEN phosphorylation and that progesterone increased PTEN protein expression in isolated endometrial, stromal and epithelial cells.”
BackgroundDalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0000000000000015 · Cited by 91 · cited 1×
“A recent review highlighted positive impacts of SARMs on cancer-associated muscle wasting (Dalton et al. 2013).”
BackgroundLanzino, M., Sisci, D., Morelli, C., Garofalo, C., Catalano, S., Casaburi, I., Capparelli, C., Giordano, C., Giordano, F., Maggiolini, M., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq278 · Cited by 90 · cited 2×
“Interestingly, cyclin D1 (CCND1), a protein which is important in regulating the cell cycle is reported to be AR regulated (Lanzino et al. 2010).”
BackgroundConsortium analysis of 7 candidate SNPs for ovarian cancer
Ramus, S. J., Vierkant, R. A., Johnatty, S. E., Pike, M. C., Berg, D. J. V. D., Wu, A. H., Pearce, C. L., Menon, U., Gentry‐Maharaj, A., Gayther, S. A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23448 · Cited by 88 · cited 1×
“However, a subsequent analysis by the ovarian cancer consortium in a large pooled sample of 4624 invasive epithelial cancer cases and 8113 controls found no association between SRD5A1 and ovarian cancer risk (Ramus et al. 2008).”
ResultExpression of androgen receptor and 5α‐reductases in the human normal endometrium and its disorders
Ito, K., Suzuki, T., Akahira, J., Moriya, T., Kaneko, C., Utsunomiya, H., Yaegashi, N., Okamura, K., & Sasano, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10394 · Cited by 88 · cited 3×
“Analysis of endometrioid carcinoma tissue homogenates confirmed mRNA expression of AR, 5a-reductase types 1 and 2 in the majority of cases (Ito et al. 2002).”
BackgroundThe human ovarian surface epithelium is an androgen responsive tissue
Edmondson, R. J., Monaghan, J., & Davies, B. R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600154 · Cited by 88 · cited 1×
“…cell type for some ovarian cancers (Auersperg 2013), the fact that both OSE cells and cells within the fallopian tube epithelium express AR (Edmondson et al. 2002, Horne et al. 2009, Mendez et al. 2013) highlights the potential for androgens to modulate disease development and progression.”
BackgroundBanks, E., REEVES, G. K., Beral, V., Bull, D., Crossley, B., Simmonds, M., Hilton, E., Bailey, S., Barrett, N. K., Briers, P., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1364 · Cited by 85
Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer
Rižner, T. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.026 · Cited by 85 · cited 1×
“A recent review from the same group concluded that due to the limitations of the available studies on AKR1C3 protein expression, the importance of AKR1C3 in EC pathophysiology requires further investigation (Rizner 2013).”
BackgroundTumor estrogen content and clinico-morphological and endocrine features of endometrial cancer
Berstein, L. M., Tchernobrovkina, A. E., Gamajunova, V. B., Ковалевский, А. Ю., Vasilyev, D. A., Чепик, О. Ф., Turkevich, E. A., Tsyrlina, E. V., Maximov, S., Андреевич, А. Л., et al. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0427-9 · Cited by 84 · cited 1×
“Notably, concentrations of E2 measured in EC tumour tissues are higher than those of disease-free endometrium (Berstein et al. 2003).”
BackgroundBirkeland, E., Wik, E., Mjøs, S., Hoivik, E. A., Trovik, J., Werner, H. M. J., Kusonmano, K., Petersen, K., Raeder, M. B., Holst, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.477 · Cited by 84 · cited 2×
“The authors report that mRNA expression levels and KRAS amplification were increased significantly in metastatic compared with primary lesions consistent with involvement of KRAS alterations in disease progression (Birkeland et al. 2012).”
BackgroundYamamoto, T., Kitawaki, J., Urabe, M., Honjo, H., Tamura, T., Noguchi, T., Okada, H., Sasaki, H., Tada, A., Terashima, Y., et al. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90251-q · Cited by 82 · cited 2×
“STS activity is reported to be higher in EC tissue compared with normal endometrium (Yamamoto et al. 1993), and more recent studies have reported that STS mRNA levels are increased in tumoural endometrial tissues compared with peri-tumoural endometrial tissues (Lepine et al.”
ResultLin, H., Sun, M., Lin, C., Tang, H.-Y., London, D., Shih, A., Davis, F. B., & Davis, P. J. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.12.010 · Cited by 82 · cited 3×
“Following reports that DHT could induce proliferation of ERa-positive and ERa-negative breast cancer cell lines via distinct mechanisms (Lin et al. 2009a), Need et al. (2012) used the ChIP-Seq technology to demonstrate reciprocal interference between DHT- and E2-induced gene expression profiles and…”
BackgroundMethodInfluentialHackenberg, R., & Schulz, K.-D. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00228-6 · Cited by 80
Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer.
Cottreau, C. M., Ness, R. B., Modugno, F., Allen, G. O., & Goodman, M. T. (2003) · PubMed · Cited by 80
Wang, H., Song, K., Sponseller, T. L., & Danielpour, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411575200 · Cited by 78 · cited 1×
“Additional data examining the AR-associated protein HIC5 (TGFB1I1) in this interaction highlight a complex interplay between these signalling pathways and cancer progression (Wang et al. 2005, Song et al. 2010).”
BackgroundBeesley, J., Jordan, S. J., Spurdle, A. B., Song, H., Ramus, S. J., Kjaer, S. K., Hogdall, E., DiCioccio, R. A., McGuire, V., Whittemore, A. S., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0542 · Cited by 76 · cited 1×
“Beesley et al. (2007) assessed putative SNPs in genes involved in steroid hormone synthesis and found an increased risk of epithelial ovarian cancer associated with a SNP in the 5a-reductase gene (SRD5A2 V89L).”
BackgroundLépine, J., Audet-Walsh, E., Grégoire, J., Têtu, B., Plante, M., Ménard, V., Ayotte, P., Brisson, J., Caron, P., Villeneuve, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2648 · Cited by 75 · cited 2×
“1993), and more recent studies have reported that STS mRNA levels are increased in tumoural endometrial tissues compared with peri-tumoural endometrial tissues (Lepine et al. 2010).”
BackgroundResultAttenuated Sex Steroid Receptor Expression in Fallopian Tube of Women with Ectopic Pregnancy
Horne, A. W., King, A. E., Shaw, E., McDonald, S. E., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1476 · Cited by 73 · cited 3×
“2000), fallopian tube (Horne et al. 2009) and endometrium (Marshall et al.”
BackgroundSelf-citationKoivisto-Korander, R., Bützow, R. C., Koivisto, A., & Leminen, A. (2010) · Tumor Biology · doi:10.1007/s13277-010-0138-1 · Cited by 71 · cited 1×
“A recent analysis of uterine sarcomas failed to identify AR expression in uterine carcinosarcoma, leiomyosarcoma or endometrial stromal sarcoma (Koivisto-Korander et al. 2011).”
BackgroundCollins, F., MacPherson, S., Brown, P., Bombail, V., Williams, A. R., Anderson, R. A., Jabbour, H. N., & Saunders, P. T. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-330 · Cited by 70 · cited 2×
“Endometrial cancer cells from a dataset described previously in Collins et al. (2009) were immunostained using rabbit anti-human AR (Abcam, Cambridge, UK) in 1:100 dilution (see Marshall et al. (2011), with detection using DAB as described in Collins et al. (2009)).”
MethodResultSelf-citationSasaki, M., Oh, B. R., Dharia, A., Fujimoto, S., & Dahiya, R. (2000) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200010)29:2<59::aid-mc2>3.0.co;2-6 · Cited by 69 · cited 4×
“Epigenetic regulation of the AR gene has also been implicated in endometrial malignancy, with hypermethylation of a CpG region spanning the transcription start site being associated with AR gene inactivation in EC patients (Sasaki et al. 2000).”
BackgroundResultInfluentialPossible association between gastric cancer and bracken fern in Venezuela: An epidemiologic study
Alonso‐Amelot, M. E., & Avendaño, M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010115)91:2 · Cited by 66
Marshall, E., Lowrey, J., MacPherson, S., Maybin, J. A., Collins, F., Critchley, H. O. D., & Saunders, P. T. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0272 · Cited by 66 · cited 8×
“It has been reported that ARs are expressed in the endometrium throughout the menstrual cycle (Mertens et al. 2001, Apparao et al. 2002, Marshall et al. 2011).”
BackgroundMethodInfluentialSelf-citationLin, S.-L., Yan, L.-Y., Liang, X.-W., Wang, Z.-B., Wang, Z. Y., Qiao, J., Schatten, H., & Sun, Q.-Y. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-102 · Cited by 66
Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women
Zang, H., Sahlin, L., Masironi, B., Eriksson, E., & Lindén Hirschberg, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2171 · Cited by 65 · cited 1×
“For example, testosterone treatment of post-menopausal women does not appear to induce endometrial stimulation and decreases the proliferative effect of E2 (Zang et al. 2007).”
BackgroundElattar, A., Warburton, K. G., Mukhopadhyay, A., Freer, R. M., Shaheen, F. S., Cross, P., Plummer, E. R., Robson, C. N., & Edmondson, R. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.004 · Cited by 63 · cited 1×
“When Elattar et al. (2012) tested the impact of DHT on cell division in primary ovarian epithelial cancer cells isolated from the ascites of 11 patients with advanced primary ovarian cancers, they recorded variable concentrations of AR mRNA and an increase in S-phase cells, which was abrogated by…”
BackgroundEstablishment of eighteen clones of Ishikawa cells.
Nishida, M., Kasahara, K., Oki, A., Satoh, T., Arai, Y., & Kubo, T. (1996) · PubMed · Cited by 62
CyclinD1, a prominent prognostic marker for endometrial diseases
Liang, S., Mu, K., Wang, Y., Zhou, Z., Zhang, J., Sheng, Y., & Zhang, T. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-138 · Cited by 62 · cited 2×
“CCND1 expression is significantly associated with EC grade (Moreno-Bueno et al. 2003) with a recent study suggested that cyclin D1 may be a prognostic marker for endometrial diseases with overexpression of cyclin D1 in EC and atypical complex hyperplasia (Liang et al. 2013).”
BackgroundTubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case–Control Study
Rice, M. S., Murphy, M., Vitonis, A. F., Cramer, D. W., Titus, L. J., Tworoger, S. S., & Terry, K. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28249 · Cited by 61 · cited 2×
“2012) as well as tubal ligation with the latter most closely associated with endometrioid tumours (Rice et al. 2013).”
BackgroundLovely, L. P., Rao, K., Gui, Y., & Lessey, B. A. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00127-8 · Cited by 59 · cited 1×
“We, and others (Lovely et al. 2000), have consistently found that this cell expresses AR, ERa (ESR1) and ERb (ESR2).”
BackgroundSpinal and Bulbar Muscular Atrophy
Grunseich, C., & Fischbeck, K. H. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.002 · Cited by 58
DNA methylation and nucleosome occupancy regulate the cancer germline antigen geneMAGEA11
James, S. R., Cedeno, C. D., Sharma, A. K., Zhang, W., Mohler, J. L., Odunsi, K. O., Wilson, E. M., & Karpf, A. R. (2013) · Epigenetics · doi:10.4161/epi.25500 · Cited by 56 · cited 1×
“A recent report highlighted a role for promoter methylation in the regulation of expression of the AR co-activator melanoma-associated antigen 11 (MAGEA11) in ovarian and other cancers, a finding that is important as expression is correlated with poor prognosis (James et al. 2013).”
BackgroundTamm, K., Simm, J., Suhorutshenko, M., Salumets, A., & METSIS, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068907 · Cited by 55 · cited 6×
“Expression of cyclin D1 has been linked to breast cancer growth and progression, and studies on breast cancer cells have revealed that CCND1 promoter activity can be inhibited by DHT-activated AR (Lanzino et al. 2010).”
BackgroundInfluentialNuclear Receptor Profiling of Ovarian Granulosa Cell Tumors
Alexiadis, M., Eriksson, N. A., Jamieson, S., Davis, M. J., Drummond, A. E., Chu, S., Clyne, C. D., Muscat, G. E. O., & Fuller, P. J. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0069-3 · Cited by 55 · cited 3×
“We, and others (Lovely et al. 2000), have consistently found that this cell expresses AR, ERa (ESR1) and ERb (ESR2).”
InfluentialDynamic SUMOylation Is Linked to the Activity Cycles of Androgen Receptor in the Cell Nucleus
Rytinki, M. M., Kaikkonen, S., Sutinen, P., Paakinaho, V., Rahkama, V., & Palvimo, J. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-12 · Cited by 54 · cited 1×
“AR sumoylation has been demonstrated to enrich AR in the nuclear matrix under conditions of cellular stress, causing attenuation of the transcriptional activity of AR, contributing to defective androgen signalling in cancer (Poukka et al. 2000, Rytinki et al. 2012).”
BackgroundAndrogen-related expression of G-proteins in ovarian cancer
Sheach, L. A., Adeney, E. M., Kucukmetin, A., Wilkinson, S. J., Fisher, A. D., Elattar, A., Robson, C. N., & Edmondson, R. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605153 · Cited by 53
Expression and Function of Androgen Receptor Coactivator p44/Mep50/WDR77 in Ovarian Cancer
Ligr, M., Patwa, R. R., Daniels, G., Pan, L. Y., Wu, X., Li, Y., Tian, L., Wang, Z., Xu, R., Wu, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026250 · Cited by 46 · cited 2×
“R e la te d C a n ce r associated increases in cell proliferation and invasion are AR mediated (Ligr et al. 2011).”
BackgroundAndrogen receptor polymorphisms and endometrial cancer risk
McGrath, M., Lee, I., Hankinson, S. E., Kraft, P., Hunter, D. J., Buring, J., & De Vivo, I. (2006) · International Journal of Cancer · doi:10.1002/ijc.21436 · Cited by 46 · cited 1×
“Notably, an association has been reported between the number of CAG and GGN repeats in the NTD and the progression state of EC, with a prevalence of short repeats in more benign tumours (McGrath et al. 2006, Rodrı́guez et al. 2006).”
BackgroundYang, H. P., Gonzalez Bosquet, J., Li, Q., Platz, E. A., Brinton, L. A., Sherman, M. E., Lacey, J. V., Gaudet, M. M., Burdette, L. A., Figueroa, J. D., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp328 · Cited by 45 · cited 1×
“Interestingly, in an extensive analysis of common genetic variation of 36 sex hormone-related genes by Yang et al. (2010), genetic variation in AR was significantly associated (PZ0.”
BackgroundLundin, E., Wirgin, I. I., Lukanova, A., Afanasyeva, Y., Krogh, V., Axelsson, T., Hemminki, K., Clendenen, T. V., Arslan, A. A., Ohlson, N., et al. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.04.006 · Cited by 44 · cited 1×
“A recent case–control study of polymorphisms in 391 EC cases and 712 individually matched controls found that CYP19A1 variants are associated with an increased risk of EC (Lundin et al. 2012).”
Song, K. W., Wang, H., Krebs, T. L., Wang, B., Kelley, T. J., & Danielpour, D. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0165 · Cited by 43 · cited 1×
“Additional data examining the AR-associated protein HIC5 (TGFB1I1) in this interaction highlight a complex interplay between these signalling pathways and cancer progression (Wang et al. 2005, Song et al. 2010).”
BackgroundSinreih, M., Hevir, N., & Rižner, T. L. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.11.012 · Cited by 42 · cited 2×
“Interestingly, a 3.7-fold decrease in SRD5A2 expression and a threefold increase in HSD17B2 expression in tumour compared with adjacent control endometrial tissue were also reported consistent with a potential for altered intra-tumoural androgen metabolism (Sinreih et al. 2013).”
BackgroundInfluentialMutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka, B., Terlikowski, S. J., Mazurek, A., Kowalczuk, O., Niklińska, W., Chyczewski, L., & Kulikowski, M. (2009) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-009-0014-2 · Cited by 41 · cited 8×
“Utilising arraybased and sequencing technologies, ECs were classified into four major groups: i) ultramutated cancers with DNA polymerase epsilon (POLE) mutations (7%), ii) hypermutated cancers due to DNA mismatch repair and associated microsatellite instabilities (28%), iii) ECs with low mutation rate and a low frequ…”
BackgroundInfluentialAlHilli, M. M., Long, H. J., Podratz, K. C., & Bakkum-Gamez, J. N. (2011) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2011.01698.x · Cited by 40 · cited 1×
“Notably, treatment of a small group of patients with diagnosis of a GCT with aromatase inhibitors has reported positive results (Alhilli et al. 2012).”
BackgroundAndrogen receptor and 5α‐reductase are expressed in pelvic endometriosis
Carneiro, M., Morsch, D., Camargos, A., Reis, F., & Spritzer, P. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01521.x · Cited by 37 · cited 2×
“2002) or both stromal and epithelial cells (Carneiro et al. 2008).”
BackgroundAvancès, C., Georget, V., Térouanne, B., Orio, F., Cussenot, O., Mottet, N. A., Costa, P., & Sultan, C. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00669-4 · Cited by 37 · cited 2×
“DHT is the most potent endogenous AR agonist, while A4 and DHEA have extremely low binding affinity for AR (Avances et al. 2001).”
BackgroundLyu, S., Yu, Q., Ying, G., Wang, S., Wang, Y., Zhang, J., & Niu, Y. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2151 · Cited by 37 · cited 1×
“In a recent study, KRAS protein expression was reported to be decreased by AR signalling in ERK, PRK and ARC breast cancer cells (Lyu et al. 2014), which may indicate a further target for androgen therapy in EC.”
BackgroundExpression analysis of estrogen-metabolizing enzymes in human endometrial cancer
Šmuc, T., Rupreht, R. R., Šinkovec, J., Adamski, J., & Rižner, T. L. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.013 · Cited by 36 · cited 1×
“Expression and activity of STS has been reported in endometrial carcinoma cell lines (Smuc et al. 2006, Fournier & Poirier 2009).”
BackgroundRodríguez, G., Bilbao, C., Ramírez‐Moreno, R., Falcón, O., León, L., Chirino, R., Falcón, O., Díaz, B. P., Rivero, J. F., Perucho, M., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21516 · Cited by 36
Bukulmez, O., Hardy, D. B., Carr, B. R., Auchus, R. J., Toloubeydokhti, T., Word, R. A., & Mendelson, C. R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0248 · Cited by 35 · cited 1×
“Interestingly, a recent study has shown that A4 up-regulates aromatase mRNA expression in human endometrial stromal cells and explants (Bukulmez et al. 2008) underlining the importance of local bioavailability and metabolism of androgens in modulating the steroid microenvironment in the endometrium.”
BackgroundWu, Y.-G., Baumgarten, S. C., Zhou, P., & Stocco, C. O. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00011-13 · Cited by 35 · cited 2×
“have reported that testosterone, but not DHT, alters expression of aryl hydrocarbon receptor (AHR) and liver receptor homologue 1 (LRH1 (NR5A2)) with an AHR-dependent interaction between AHR and AR leading to increased expression of the LRH1 gene (Wu et al. 2013).”
BackgroundSaloniemi, T., Lamminen, T., Huhtinen, K., Welsh, M., Saunders, P. T. K., Kujari, H. P., & POUTANEN, M. H. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0144 · Cited by 34 · cited 1×
“In mice, over-expression of human HSD17B1 resulted in development of an androgen-dependent ovarian benign serous cystadenoma phenotype in adulthood (Saloniemi et al. 2007).”
BackgroundSelf-citationCao, Y., Zhang, S., Zou, S., & Xia, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058448 · Cited by 33 · cited 1×
“Furthermore, free testosterone and DHEAS are reported to correlate positively with abdominal fat accumulation in post-menopausal women (Cao et al. 2013).”
BackgroundFournier, M.-A., & Poirier, D. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.027 · Cited by 30 · cited 1×
“Expression and activity of STS has been reported in endometrial carcinoma cell lines (Smuc et al. 2006, Fournier & Poirier 2009).”
BackgroundAIB1 Polymorphisms Predict Aggressive Ovarian Cancer Phenotype
Li, A. J., Lerner, D. L., Gapuzan, M.-E. R., & Karlan, B. Y. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0540 · Cited by 30
Butler, M. S., Ricciardelli, C., Tilley, W. D., & Hickey, T. E. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0135-0 · Cited by 29 · cited 2×
“R e la te d C a n ce r (patients aged 27–86) as well as 23 samples with matched metastases was assessed and the majority demonstrated moderate to strong nuclear immunostaining for AR (Butler et al. 2013).”
BackgroundMhawech-Fauceglia, P. Y., Smiraglia, D. J., Bshara, W., Andrews, C., Schwaller, J., South, S. A., Higgs, D., Lele, S., Herrmann, F. R., & Odunsi, K. O. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0511 · Cited by 29 · cited 2×
“Interestingly, multivariate survival analysis associated loss of PSA expression with worse disease-free survival (Mhawech-Fauceglia et al. 2008).”
BackgroundShort androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma.
Li, A. J., Baldwin, R. L., & Karlan, B. Y. (2003) · PubMed · Cited by 28
Expression of androgen receptor and its phosphorylated forms in breast cancer progression
Ren, Q., Zhang, L., Ruoff, R., Ha, S., Wang, J., Jain, S., Reuter, V. E., Gerald, W. L., Giri, D. D., Melamed, J., et al. (2013) · Cancer · doi:10.1002/cncr.28092 · Cited by 27 · cited 2×
“2010) and recently investigated in the context of breast cancer (Ren et al. 2013).”
BackgroundVoet, A. R. D., Helsen, C., Zhang, K. Y. J., & Claessens, F. (2013) · ChemMedChem · doi:10.1002/cmdc.201200549 · Cited by 27 · cited 1×
“Using computational pharmacophore modelling and virtual screening, second-generation anti-androgens have been developed which could be of therapeutic benefit in treating AR-dependent ovarian cancers (Voet et al. 2013).”
BackgroundStudy, A. C., Earp, M. A., Australian Ovarian Cancer Study Group, Kelemen, L. E., Magliocco, A. M., Swenerton, K. D., Chenevix‐Trench, G., Lu, Y., Hein, A., Ekici, A. B., et al. (2013) · Human Genetics · doi:10.1007/s00439-013-1383-3 · Cited by 26 · cited 1×
“A recent GWAS study reported six loci that were associated with subtype-specific epithelial ovarian cancer risk (Earp et al. 2013) underlining the importance of redefining the origins of some subtypes.”
BackgroundGenetic changes in nonepithelial ovarian cancer
Nieuwenhuysen, E. V., Lambrechts, S., Lambrechts, D., Leunen, K., Amant, F. C., & Vergote, I. B. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.811174 · Cited by 23
Current issues in the pathology of ovarian cancer.
Rabban, J. T., & Bell, D. A. (2005) · PubMed · Cited by 22
Ochnik, A. M., Moore, N. L. T., Jankovic‐Karasoulos, T., Bianco‐Miotto, T., Ryan, N. K., Thomas, M., Birrell, S. N., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182936ef4 · Cited by 21 · cited 4×
“For example, studies on the breast have considered two aspects: anti-androgenic effects of the progestin MPA (Ochnik et al. 2014) and crosstalk between AR and ERa signalling due to overlapping binding sites withinDNA(Need et al. 2012,Ochnik et al. 2014).”
BackgroundInfluentialLiver receptor homologue-1 expression in ovarian epithelial and granulosa cell tumours
Chand, A. L., Pathirage, N. A., Lazarus, K. A., Chu, S., Drummond, A. E., Fuller, P. J., & Clyne, C. D. (2013) · Steroids · doi:10.1016/j.steroids.2013.03.001 · Cited by 19 · cited 7×
“2010), any increase in expression as a result of androgen action might promote invasiveness of granulosa cells and it is notable that LRH1 level is elevated 30-fold in GCTs (Chand et al. 2013).”
BackgroundInfluentialDiagnostic value of prostate-specific antigen in women with polycystic ovary syndrome.
Mardanian, F., & Heidari, N. (2011) · PubMed Central · Cited by 19
In vitro metabolism of C19 steroids in human endometrium
Hausknecht, V., de la Osa, E. L., & Gurpide, E. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90563-5 · Cited by 18 · cited 1×
“The endometrium is also reported to convert the adrenal androgen DHEAS to DHEA and A4 (Hausknecht et al. 1982).”
BackgroundIdentification of androgen receptor phosphorylation in the primate ovary in vivo
McEwan, I. J., McGuinness, D., Hay, C. W., Millar, R. P., Saunders, P. T. K., & Fraser, H. M. (2010) · Reproduction · doi:10.1530/rep-10-0140 · Cited by 16
Self-citationXiong, G., & Xu, R. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-2701 · Cited by 15
Preventive effects of danazol on endometrial carcinogenesis in mice
Niwa, K., Hashimoto, M., Morishita, S., Yokoyama, Y., Lian, Z., Tagami, K., Mori, H., & Tamaya, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00497-3 · Cited by 14 · cited 2×
“…q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0551 Printed in Great Britain In a mouse model of endometrial carcinogenesis, the synthetic androgen Danazol significantly decreased expression of the proliferation marker PCNA and the incidence of endometrial hyperplasia (Niwa et al. 2000).”
BackgroundInfluentialGenetic Variation in the Androgen Receptor Gene and Endometrial Cancer Risk
Yang, H., García‐Closas, M., Lacey, J. V., Brinton, L. A., Lissowska, J., Pepłońska, B., Chanock, S. J., & Gaudet, M. M. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0677 · Cited by 14 · cited 1×
“However, it should be noted that a later study reported a weak association between the CAG repeats and EC risk (Yang et al. 2009).”
BackgroundSulfatase Activity in Normal and Neoplastic Endometrium
Abulafia, O., Lee, Y.-C., Wagreich, A., Economos, K., Serur, E., & Nacharaju, V. L. (2009) · Gynecologic and Obstetric Investigation · doi:10.1159/000161571 · Cited by 12 · cited 2×
“In addition, Abulafia et al. (2009) reported significantly increased DHEAS sulphatase activity in stage I endometrioid carcinoma compared with normal endometrium consistent with a role for increased activation of androgen precursors in EC.”
BackgroundCORRELATION OF ANDROGEN RECEPTORS WITH HISTOLOGICAL DIFFERENTIATION IN HUMAN ENDOMETRIAL CARCINOMAS
Kato, J., & Seto, T. (1985) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016348509155114 · Cited by 12 · cited 1×
“AR protein levels are reported to decline as EC progresses from well- to poorly differentiated tumours (Kato & Seto 1985).”
BackgroundMéndez, C., Morales-Vásquez, F., Pérez‐Montiel, D., Gómora, M. J., Espinola-Zetina, C., Hernández-Martínez, A., López-Basave, H. N., & Pedernera, E. A. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-85 · Cited by 11 · cited 1×
“…cell type for some ovarian cancers (Auersperg 2013), the fact that both OSE cells and cells within the fallopian tube epithelium express AR (Edmondson et al. 2002, Horne et al. 2009, Mendez et al. 2013) highlights the potential for androgens to modulate disease development and progression.”
BackgroundVera, L., Accornero, M., Mora, M., Valenzano-Menada, M., Minuto, F. M., & Giusti, M. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743012 · Cited by 9 · cited 1×
“Adult GCTs are thought to arise from granulosa cells in late pre-ovulatory follicles and similar to their pre-malignant counterparts they secrete steroids including oestrogen, and in rare cases, patients may present with evidence of hyperandrogenism (Vera et al. 2013).”
BackgroundReduction of Testosterone to 5α-Dihydrotestosterone by Human and Rat Uterine Tissues*
Rose, L. I., Reddy, V. V. R., & Biondi, R. J. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-5-766 · Cited by 7 · cited 1×
“In studies using human endometrial explants (Rose et al. 1978), 5a-reductase has also been shown to reduce testosterone to DHT consistent with local androgen activation in intact tissue.”
Background
Research works printed but not linked: 9
- 2008, NUCLEAR RECEPTOR SIGNALING, 6, 008e
- Horie, 1992, Human Reproduction, 7, 184, 10.1093/humrep/ · doi:10.1093/humrep/
- Li, 2003, Clinical Cancer Research, 9, 3667
- 2011, JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 16, 999
- 1996, HUMAN CELL, 9, 109
- 2013, INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS, 124, 1
- Rabban, 2005, The Journal of reproductive medicine, 50, 467
- Syed, 2001, Cancer Research, 61, 6768
- 2013, EMBO MOLECULAR MEDICINE, 5, 983
Cited by
Wang, Y.-X., Arvizu, M., Rich-Edwards, J. W., Stuart, J. J., Manson, J. E., Missmer, S. A., Pan, A., & Chavarro, J. E. (2020) · BMJ · doi:10.1136/bmj.m3464 · Cited by 178
Wiwatpanit, T., Murphy, A. R., Lu, Z., Urbanek, M., Burdette, J. E., Woodruff, T. K., & Kim, J. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz100 · Cited by 135
Androgens and endometrium: new insights and new targets
Simitsidellis, I., Saunders, P. T. K., & Gibson, D. A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.022 · Cited by 107
Self-citationEpidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences
Felix, A. S., Yang, H., Bell, D. W., & Sherman, M. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_1 · Cited by 107
SiRNA and epigenetic aberrations in ovarian cancer
Mirzaei, H., Yazdi, F., Salehi, R., & Mirzaei, H. R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.153661 · Cited by 106
Metadata
- Authors
- Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K.
- Affiliations
- MRC Centre for Reproductive Health (GB)
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-02-28
- Volume
- 21
- Issue
- 4
- Pages
- T203-T218
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108865532
- Cited by
- 73
- References
- 154
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 11 · 2015: 4 · 2014: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- androgen action, endometrial cancer, ovarian cancer, androgen receptor, androgen signaling, androgen production, genetic variants, cancer risk, antiandrogen therapy, tumor progression, endometrium, ovary
- MeSH terms
- Androgen Antagonists, Androgens, Endometrium, Female, Humans, Ovarian Neoplasms, Ovary, Receptors, Androgen, Endometrial Neoplasms, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.